The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

That it was delivered by Nobel Laureate and Janssen Award winner Craig Mello only underscored its import. On that balmy, late summer evening in 2014, in a stately, yet intimate ballroom at the ...

Co-founded by Craig Mello, who won the Nobel Prize for Physiology or Medicine in 2006 for his work on RNAi, the company says the technology could be used to treat central nervous system diseases ...